Not FDA-approved3Evidence: Limited human dataHormones

GHRP-61,3

Also called Growth hormone-releasing peptide 61

Key takeaway

GHRP-6 (growth hormone-releasing peptide 6) is a synthetic six-amino-acid peptide that FDA’s substance registry also records as hexapeptide-2.1 FDA has placed GHRP-6 in category 2 of its compounding lists, for substances that may present significant safety risks, citing possible immune reactions and possible effects on cortisol and blood sugar.3 No FDA approval is reported in the sources reviewed here, and GHRP-6 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.3,5

GHRP-6 at a glance

What it isA synthetic hexapeptide amide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2), also recorded as hexapeptide-2 and SK&F-110679, according to FDA’s substance registry.1
FDA statusNo FDA approval is reported in the sources reviewed here. Since September 29, 2023, FDA has listed GHRP-6 in category 2 under its interim policy for outsourcing facilities, for substances that may present significant safety risks.3
Human evidenceSmall studies of how the body handles it, such as a 2013 study in nine healthy men. FDA reports only limited safety information.2,3
Evidence strengthLimited human data. The only cited human studies are small, short, uncontrolled, or incompletely reported, such as case series, pilot studies, or trials published only as a conference abstract whose methods and results cannot be checked. How this label is assigned

What is GHRP-6?

GHRP-6 is a synthetic peptide of six amino acids, two of them in the unnatural D form, ending in an amide. FDA’s substance registry records it as hexapeptide-2, growth hormone-releasing peptide 6 and SK&F-110679.1

How is GHRP-6 thought to work?

Its registered name, growth hormone-releasing peptide 6, describes its intended action of prompting the release of growth hormone. The authors of a 2013 study describe it as a growth hormone secretagogue.1,2

FDA states that the available data raise concerns about possible effects on cortisol and a rise in blood sugar from reduced insulin sensitivity.3

What do human studies show?

A 2013 study gave GHRP-6 to nine healthy men to measure how it is distributed and cleared. It reported a distribution half-life of about eight minutes and an elimination half-life of about two and a half hours.2

FDA reports that it has identified only limited safety-related information on GHRP-6. The sources reviewed here do not include trials of whether it is effective for any use.2,3

What the evidence base contains

  • Small, short, or incompletely reported human study A 2013 pharmacokinetic study in nine healthy men, which measured how quickly GHRP-6 is distributed and cleared, without a comparison group.2

Evidence-strength label: Limited human data. How this label is assigned

Is GHRP-6 FDA-approved?

None of the sources reviewed here reports an approval of GHRP-6 by FDA.1,3

FDA’s compounding safety-risk page, current as of April 22, 2026, lists GHRP-6 in category 2 under the interim policy for outsourcing facilities (section 503B) since September 29, 2023, citing possible immune reactions from aggregation and impurities.3

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. GHRP-6 is not among them.4,5

Timeline

  1. A pharmacokinetic study of GHRP-6 in nine healthy men is published.2
  2. FDA places GHRP-6 in category 2 under its 503B interim compounding policy, according to its safety-risk page.3
  3. FDA’s compounding safety-risk page, as last updated, keeps GHRP-6 in category 2.3

What is still unknown?

Whether it is effective for any condition, which none of the sources reviewed here evaluates.2,3

How safe it is: FDA states that it has only limited safety-related information.3

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for GHRP-6: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for GHRP-6 are a bounded selection, not every registration or paper about GHRP-6. For the years before GHRP-6 was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list GHRP-6 as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name GHRP-6 in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

No FDA approval reported; on FDA’s compounding safety-risk list (category 2). Human data are limited to small studies such as a pharmacokinetic study in nine healthy men. No FDA approval is reported in the cited sources, and GHRP-6 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗

Status sources checked through November 14, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of GHRP-6?

No FDA approval reported; on FDA’s compounding safety-risk list (category 2). Human data are limited to small studies such as a pharmacokinetic study in nine healthy men. No FDA approval is reported in the cited sources, and GHRP-6 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗

The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
1
Source years
7
Drugs@FDA applications
0

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Collection changes

What did PeptideScanner add most recently?

  1. Literature metadata · added November 16, 2026

    GHRP-6 in heifer and cow adenohypophisial cells separated by elutriation.↗Source date November 1, 2026
  2. Literature metadata · added November 16, 2026

    Growth hormone (GH) peaks versus areas under the curve in the diagnosis of adult GH deficiency: analysis of the variables provided by the GHRH + GHRP-6 test.↗Source date October 19, 2026
  3. Literature metadata · added November 16, 2026

    Impairment of GH responsiveness to GH-releasing hexapeptide (GHRP-6) in Prader-Willi syndrome.↗Source date October 12, 2026

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected clinical trial records, regulatory records, and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to GHRP-6?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

25Selected dated records
30Connected citations
7Populated source years2016–2026
1/4Record lanes present

Registered human studies

Trial composition

0 of 0 selected trial records include at least one phase value; 0 of 0 include a status value in the retained structured contract.

PubMed bibliography

Publication composition

25 of 25 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 25Research Support, Non-U.S. Gov't 11Comparative Study 3Evaluation Study 2Research Support, N.I.H., Intramural 2Review 2Clinical Trial 1Validation Study 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
0
FDA Federal Register documents
0
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
25

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 25 dated records

Research hub

Explore the GHRP-6 evidence record

Open all 25 records →
25Dated records
1Evidence type
25Cited public sources
7Source years

Change ledger

Recently changed for GHRP-6

Open all 25 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

An electrophysiological and morphological investigation of the projections of growth hormone-releasing peptide-6-responsive neurons in the rat arcuate nucleus to the median eminence and to the parave…

PubMed lists PMID 10218787 in Neuroscience as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1999-03 (month precision). PeptideScanner associated the retained record with the identity slug ghrp-6. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
July 12, 2019
Evidence lane
Literature metadata
Record added

Antiproliferative and GH-inhibitory activity of chimeric peptides consisting of GHRP-6 and somatostatin.

PubMed lists PMID 10362518 in Biochemical and biophysical research communications as Journal Article, with publication-date metadata of 1999-06-07 (day precision). PeptideScanner associated the retained record with the identity slug ghrp-6. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
November 24, 2016
Evidence lane
Literature metadata
Record added

GHRP-6 in heifer and cow adenohypophisial cells separated by elutriation.

PubMed lists PMID 10494658 in Journal of physiology and biochemistry as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1999-03 (month precision). PeptideScanner associated the retained record with the identity slug ghrp-6. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
November 1, 2026
Evidence lane
Literature metadata

Official-source collections

Source records for GHRP-6

Open the full research atlas →

Evidence types

Coverage by source year

Selected records span November 23, 2016 to November 1, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. Food and Drug Administration1,3
  • U.S. Department of Health and Human Services4
Dated updates connected to this profile · 25

Updates connected to this profile

Open the full cross-source timeline →
  1. Literature metadata

    GHRP-6 in heifer and cow adenohypophisial cells separated by elutriation.↗

    PubMed lists PMID 10494658 in Journal of physiology and biochemistry as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1999-03 (month precision). PeptideScanner associated the retained record with the identity slug ghrp-6. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Growth hormone (GH) peaks versus areas under the curve in the diagnosis of adult GH deficiency: analysis of the variables provided by the GHRH + GHRP-6 test.↗

    PubMed lists PMID 15638293 in Pituitary as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2004 (year precision). PeptideScanner associated the retained record with the identity slug ghrp-6. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Impairment of GH responsiveness to GH-releasing hexapeptide (GHRP-6) in Prader-Willi syndrome.↗

    PubMed lists PMID 11407654 in Journal of endocrinological investigation as Journal Article, with publication-date metadata of 2001-05 (month precision). PeptideScanner associated the retained record with the identity slug ghrp-6. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    Role of epidermal growth factor and growth hormone-releasing peptide-6 in acceleration of renal tissue repair after kanamycin overdosing in rats.↗

    PubMed lists PMID 25194405 in Iranian journal of kidney diseases as Journal Article, with publication-date metadata of 2014-09 (month precision). PeptideScanner associated the retained record with the identity slug ghrp-6. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    Formation of acylated growth hormone-releasing peptide-6 by poly(lactide-co-glycolide) and its biological activity.↗

    PubMed lists PMID 17622118 in AAPS PharmSciTech as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2007-06-08 (day precision). PeptideScanner associated the retained record with the identity slug ghrp-6. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Literature metadata

    A discovery-based proteomic approach of epidermal growth factor and growth hormone-releasing peptide-6 in a model of acute ischemic stroke.↗

    PubMed lists PMID 42258095 in Pharmacological reports : PR as Journal Article, with publication-date metadata of 2026-06-08 (day precision). PeptideScanner associated the retained record with the identity slug ghrp-6. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Literature metadata

    Development and validation of a bioanalytical LC-MS method for the quantification of GHRP-6 in human plasma.↗

    PubMed lists PMID 22154075 in Journal of pharmaceutical and biomedical analysis as Journal Article, Validation Study, with publication-date metadata of 2011-11-15 (day precision). PeptideScanner associated the retained record with the identity slug ghrp-6. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Literature metadata

    Interaction of the growth hormone-releasing peptides ghrelin and growth hormone-releasing peptide-6 with the motilin receptor in the rabbit gastric antrum.↗

    PubMed lists PMID 12606621 in The Journal of pharmacology and experimental therapeutics as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2003-02-11 (day precision). PeptideScanner associated the retained record with the identity slug ghrp-6. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Literature metadata

    The GHS-R blocker D-[Lys3] GHRP-6 serves as CCR5 chemokine receptor antagonist.↗

    PubMed lists PMID 22211090 in International journal of medical sciences as Journal Article, Research Support, N.I.H., Intramural, with publication-date metadata of 2011-11-18 (day precision). PeptideScanner associated the retained record with the identity slug ghrp-6. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  10. Literature metadata

    Identification of ghrelin receptor blocker, D-[Lys3] GHRP-6 as a CXCR4 receptor antagonist.↗

    PubMed lists PMID 22211109 in International journal of biological sciences as Journal Article, Research Support, N.I.H., Intramural, with publication-date metadata of 2011-11-26 (day precision). PeptideScanner associated the retained record with the identity slug ghrp-6. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  11. Literature metadata

    D-Lys-3-GHRP-6 impairs memory consolidation and downregulates the hippocampal serotonin HT1A, HT7 receptors and glutamate GluA1 subunit of AMPA receptors.↗

    PubMed lists PMID 32454141 in Physiology & behavior as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2020-05-23 (day precision). PeptideScanner associated the retained record with the identity slug ghrp-6. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  12. Literature metadata

    A single growth hormone (GH) determination is sufficient for the diagnosis of GH-deficiency in adult patients using the growth hormone releasing hormone plus growth hormone releasing peptide-6 test.↗

    PubMed lists PMID 12201831 in Clinical endocrinology as Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2002-09 (month precision). PeptideScanner associated the retained record with the identity slug ghrp-6. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    GHRP-6 (hexapeptide-2) substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  2. 2
    Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers (2013) · PMID 23099431 ↗

    European Journal of Pharmaceutical Sciences · Official source · Source checked November 15, 2026

  3. 3
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  4. 4
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  5. 5
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026